微信直播

WCLC 2017专访 | Dr. Peter Ujhazy:学术研究与临床实践相结合,使患者获益最大化

Published at: 2015年第1卷第S1期

AME
关键词:

编者按2017年10月15日-18日,由国际肺癌研究协会(IASLC)举办的第18届世界肺癌大会于日本美丽的港口都市横滨圆满召开。此次学术盛会吸引了全世界众多从事肺癌研究,临床工作及预防控制领域的专家学者关注和参会。来自美国国家癌症研究所(National Cancer Institute, NCI)癌症治疗与诊断部门的Dr. Peter Ujhazy在会议上进行了主题为“NCI’s Small Cell Lung Cancer Consortium: New Answers to Old Questions”的演讲。AME编辑很荣幸采访到他,听他分享研究小细胞肺癌中需要优先考虑的五大问题及美国国家癌症研究所小细胞肺癌联盟正在进行的重点研究项目(图 1)。

人物聚焦:Peter Ujhazyr

Peter Ujhazy is the Deputy Associate Director of the Translational Research Program, Division of Cancer Treatment and Diagnosis at the National Cancer Institute.

He has received his Medical Degree at the Comenius University, and his Ph.D. at the Cancer Research Institute of the Slovak Academy of Sciences in Bratislava, Czechoslovakia, where he started his career in the Department of Tumor Immunology. 

He was involved in the development of diagnostics in blood malignancies, he studied natural immunity in lymphoid malignancies, and gained clinical experience in the adjacent Cancer Center. 

He worked for 6 years as a Visiting Scientist and later as a Cancer Research Scientist in Dr. Henry Mihich’s laboratory at Roswell Park Cancer Institute in Buffalo, NY, USA and published extensively on chemo-immunotherapy and multidrug resistance. 

After a short stay in the biotech company Biotech Research Laboratories in the Washington, DC metropolitan area, he decided not to pursue a career in industry and accepted a position in Dr. Irvin Arias’ laboratory in the Department of Physiology, Tufts University in Boston, MA, where he studied the physiologic role of ATP-dependent transporters. 

In 2001, Dr. Ujhazy accepted a position in the National Cancer Institute’s Organ Systems Branch that managed Specialized Programs of Research Excellence (SPOREs). Working with SPOREs grants brought him closer to the ultimate goal of his original training — that is to help patients and populations at risk of cancer. 

Over the past 14 years, Dr. Ujhazy has served as the Program Director for Lung, Leukemia, Lymphoma, Myeloma, Sarcoma, GI, Pancreas, Head & Neck, and Brain Tumor SPOREs. Currently, he is in charge of SPOREs in Lung cancer, Myeloma, and Sarcoma. His other duties include serving on various NCI committees and working groups.

图1. Dr Peter Ujhazy(右)与AME科学编辑于第18届世界肺癌大会期间在AME展位前合影

在采访中,Dr. Peter Ujhazy 谈到:2013年到2014年期间,NCI召集了世界各地的科学研究人员来共同探讨一个问题——研究小细胞肺癌首先要做的事情有哪些?这个问题看似简单,实则十分复杂。综合各方研究者的意见,最终得出需要优先考虑的几大问题:研发更好的研究设备、对小细胞肺癌进行全面的基因组分析、创建新的诊断和预防方法、更多的治疗进展工作等。同时,Dr. Ujhazy 还介绍了美国国家癌症研究所小细胞肺癌联盟正在进行的6项重点研究,以及研究所面临的挑战。作为一位资深的专家,在采访的结束前,他给年轻的研究者提了几条宝贵的建议。他认为学术研究必须严谨,是没有捷径可走的,研究的数据必须要百分百确定才能发表。最后他强调,学术研究要与临床实践相结合,学术研究者需要了解临床医生所面临的问题,要让自己的研究切合患者的需求,使患者获益,这样的研究才是最有意义的。

采访问题

  1. Your presentation in WCLC this year is related to small cell lung cancer (SCLC). What are the priorities in SCLC?

  2. As one of the leading experts in NCI SCLC consortium, would you like introduce the research projects undertaking in this consortium?

  3. What are the challenges in handling these projects?

  4. You are an experienced and outstanding expert, would you like to give some advices to the young investigators?

更多精彩内容,请观看下方视频:


采访编辑:刘小妹,AME Publishing Company

撰写编辑:刘小妹、Bella Poon,AME Publishing Company

视频编辑:麦雪芳,AME Publishing Company

责任编辑:陈媛玲,AME Publishing Company

学术审核:张开平,AME Publishing Company

comments powered by Disqus

附件